Noveko International (TSX: T.EKO, Stock Forum) shares were up 12.5% to $2.42 Tuesday, after the air filter, face mask and antimicrobial product developer announced that it has received preliminary results of tests on the Noveko antimicrobial masks with respect to the Influenza A Virus (H1N1), similar to the one responsible for the human swine flu.
Noveko says the purpose of the tests was to evaluate the effectiveness of the company’s face mask materials to inactivate this virus on direct contact and to simulate the use of the face mask by a user.
“The preliminary results have demonstrated a bio-efficacy of a Log 3 Reduction over a period of 30 minutes,” says the Montreal-based company.
"These preliminary results are very encouraging since they show the effectiveness of our masks to inactivate the Human Influenza A Virus (H1N1) at 99.9% over a period of 30 minutes. Even if the spread of the human swine flu currently appears to be in a declining phase, many scientists fear a more severe outbreak in fall. We thus anticipate that our sales of face masks and of our AZURO(TM) antiseptic disinfectants should increase in the next few months", says Alain Bolduc, the company’s president and COO.
On the company’s Bullboard, FredCailloux said: “I'm very concerned because I think Q3 is going to drop the share price unless there's an amazing news regarding Q4 sales[sic]”…